Trans-arterial tirapazamine embolization for Liver Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Liver Cancer+3 MoreTrans-arterial tirapazamine embolization - CombinationProduct
Eligibility
18 - 80
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new treatment for liver cancer that involves using a PD-1 checkpoint inhibitor drug after Trans-arterial Tirapazamine Embolization (TATE) treatment.

Eligible Conditions
  • Liver Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Stomach Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: through study completion, an average of 3 years

Year 3
Overall survival
up to 24 months
Duration of Response
Overall Response Rate
Overall Response rate
Progression Free Survival
Response rate
Time to Progression

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

6 Treatment Groups

Hepatocellular carcinoma
1 of 6
Metastatic Gastro-esophageal cancer
1 of 6
Colorectal cancer
1 of 6
Gastric cancer
1 of 6
NSCLC
1 of 6
Advanced Hepatocellular carcinoma
1 of 6

Experimental Treatment

54 Total Participants · 6 Treatment Groups

Primary Treatment: Trans-arterial tirapazamine embolization · No Placebo Group · Phase 2

Hepatocellular carcinomaExperimental Group · 2 Interventions: Trans-arterial tirapazamine embolization, Opdivo Injectable Product or Keytruda Injectable Product · Intervention Types: CombinationProduct, Drug
Metastatic Gastro-esophageal cancerExperimental Group · 2 Interventions: Trans-arterial tirapazamine embolization, Nivolumab Injectable Product · Intervention Types: CombinationProduct, Drug
Colorectal cancerExperimental Group · 2 Interventions: Trans-arterial tirapazamine embolization, Opdivo Injectable Product or Keytruda Injectable Product · Intervention Types: CombinationProduct, Drug
Gastric cancerExperimental Group · 2 Interventions: Trans-arterial tirapazamine embolization, Opdivo Injectable Product or Keytruda Injectable Product · Intervention Types: CombinationProduct, Drug
NSCLCExperimental Group · 2 Interventions: Trans-arterial tirapazamine embolization, Opdivo Injectable Product or Keytruda Injectable Product · Intervention Types: CombinationProduct, Drug
Advanced Hepatocellular carcinomaExperimental Group · 2 Interventions: Trans-arterial tirapazamine embolization, Nivolumab Injectable Product · Intervention Types: CombinationProduct, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 3 years

Who is running the clinical trial?

Teclison Ltd.Lead Sponsor
3 Previous Clinical Trials
294 Total Patients Enrolled
Nadine Abi-Jaoudeh, MDPrincipal InvestigatorUC Irvine Medical Center
4 Previous Clinical Trials
385 Total Patients Enrolled
1 Trials studying Liver Cancer
186 Patients Enrolled for Liver Cancer

Eligibility Criteria

Age 18 - 80 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have Child-Pugh scores of 5-7.
You have a confirmed diagnosis of advanced HCC or metastatic gastric cancer.
Patients with HCC should have progressive disease (PD) on the first line immune therapy for advanced HCC